# Junta clínica — PT-pseudo_c12bcf838ec8 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_c12bcf838ec8",
  "pid": "PT-pseudo_c12bcf838ec8",
  "task": 1,
  "psa": 3.4,
  "age": 63,
  "months": 2,
  "pirads": "3",
  "psad": 0.05,
  "psav": -0.28,
  "psap": 3.5,
  "vol": 58.0,
  "dre": "Normal",
  "bx": "Negative",
  "cspca": 0.71182245,
  "medhx": "Obesity (BMI >30), Osteoarthritis",
  "meds": "paracetamol PRN",
  "notes": "PSA 3.4 ng/mL. PI-RADS 3. PSAD 0.05. Prostate volume 58 mL. csPCa 0.71.",
  "pmhx": [
    "Obesity (BMI >30)",
    "Osteoarthritis"
  ],
  "allergies": [],
  "vitals": {
    "weight": "75 kg",
    "height": "183 cm",
    "bmi": "22.4",
    "bp": "111/68 mmHg",
    "hr": "68 bpm",
    "smoking": "Ex-smoker (23 pack-yr, quit 2011)",
    "last_dental": "1 yr ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "28 Feb 2025",
  "enc_ref": "Dr. T. Hendriks (GP)",
  "enc_type": "Re-evaluation - prior negative biopsy",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "A request for clinical reassessment has been submitted after the initial biopsy returned negative and recent MRI results are now available."
    },
    {
      "s": "History",
      "t": "First assessed in May 2022 due to a PSA elevation, this 63-year-old gentleman has since completed a negative biopsy and entered serial monitoring. He works as a retired bank clerk, is divorced, and resides alone with his adult son living nearby as his main contact. A history of smoking covers 23 pack-years, though he quit in 2011. He stays active with twice-weekly tennis matches and drinks no alcohol. Lower urinary tract symptoms remain minimal, scoring 4 out of 35 on the IPSS. Recent administrative records note he lives more than 90 minutes from the clinic, favoring telephone follow-up when clinically suitable. Earlier this month, he underwent a routine audiology check for mild hearing changes and has a gastroenterology surveillance colonoscopy scheduled; neither impacts his urological pathway. His medical background includes osteoarthritis and obesity (BMI >30), currently managed with paracetamol on an as-needed basis. He explicitly denies bone pain, haematuria, or unexplained weight loss."
    },
    {
      "s": "Physical examination",
      "t": "Normal DRE: texture smooth and firm, no palpable nodules or asymmetry. The gland is symmetrically enlarged. General assessment shows stable vital signs, registering a blood pressure of 111/68 mmHg and a heart rate of 68 bpm. Peripheral lymphadenopathy and abdominal masses are absent."
    }
  ],
  "occupation": "retired bank clerk",
  "marital": "Divorced",
  "living": "Lives alone; adult son nearby",
  "next_of_kin": "Adult son (primary contact)",
  "recent_other": [
    "Audiology — hearing test",
    "Gastroenterology — surveillance colonoscopy"
  ],
  "alcohol": "0 units / week (alcohol-free)",
  "exercise": "Tennis 2x/week",
  "ipss": "IPSS score: 4/35 (mild LUTS)",
  "admin": "Lives >90 min from clinic; phone follow-up preferred where clinically safe.",
  "mri_hospital": "Antoni van Leeuwenhoek",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_c12bcf838ec8
Task: 1

Encounter: Urology - outpatient on 28 Feb 2025.
Referrer: Dr. T. Hendriks (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 63-year-old male
  - PSA: 3.4 ng/mL
  - mpMRI — PI-RADS score: 3 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.05 ng/mL²
  - PSA velocity: -0.28 ng/mL/yr
  - Prior PSA: 3.5 ng/mL
  - Prostate volume: 58.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.71182245 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Obesity (BMI >30), Osteoarthritis
  - Problem list / PMHx: Obesity (BMI >30), Osteoarthritis
  - Current medication: paracetamol PRN
  - Allergies: NKA
  - Additional notes: PSA 3.4 ng/mL. PI-RADS 3. PSAD 0.05. Prostate volume 58 mL. csPCa 0.71.

Vitals: weight 75 kg, height 183 cm, BMI 22.4, BP 111/68 mmHg, HR 68 bpm. Smoking: Ex-smoker (23 pack-yr, quit 2011).

Chief complaint: A request for clinical reassessment has been submitted after the initial biopsy returned negative and recent MRI results are now available.

History: First assessed in May 2022 due to a PSA elevation, this 63-year-old gentleman has since completed a negative biopsy and entered serial monitoring. He works as a retired bank clerk, is divorced, and resides alone with his adult son living nearby as his main contact. A history of smoking covers 23 pack-years, though he quit in 2011. He stays active with twice-weekly tennis matches and drinks no alcohol. Lower urinary tract symptoms remain minimal, scoring 4 out of 35 on the IPSS. Recent administrative records note he lives more than 90 minutes from the clinic, favoring telephone follow-up when clinically suitable. Earlier this month, he underwent a routine audiology check for mild hearing changes and has a gastroenterology surveillance colonoscopy scheduled; neither impacts his urological pathway. His medical background includes osteoarthritis and obesity (BMI >30), currently managed with paracetamol on an as-needed basis. He explicitly denies bone pain, haematuria, or unexplained weight loss.

Physical examination: Normal DRE: texture smooth and firm, no palpable nodules or asymmetry. The gland is symmetrically enlarged. General assessment shows stable vital signs, registering a blood pressure of 111/68 mmHg and a heart rate of 68 bpm. Peripheral lymphadenopathy and abdominal masses are absent.

Patient info: retired bank clerk; Divorced; Lives alone; adult son nearby.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Tennis 2x/week; IPSS score: 4/35 (mild LUTS).

Recent other appointments: Audiology — hearing test; Gastroenterology — surveillance colonoscopy.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.33
  uncertainty  +/- 0.16 epistemic (95% band 0.03-0.64); among patients I cannot tell apart the outcome was 0.92 of 1.00 mixed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior negative biopsy. My criterion answers DEFER.

The criterion: repeat, targeted, when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for an unchanged PI-RADS 3 or lower picture. In the labelled series this criterion matched the reading urologist in 16 of 18 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 18 labelled men in this same situation (Negative prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.00 — IDENTICAL PANEL: this is the same case, already in the labelled series: PI-RADS 3, PSA 3.4, PSAD 0.05, age 63, DRE Normal -> DEFER (clear). He wrote: "Prev benign biopsy + PIRADS 3 (=no significant lesion) + low PSA-density -> Low longterm risk of lethal prostate cancer. 2yr too short interval for next assessment. sugg…"
  2. distance 1.58: PI-RADS 3, PSA 7.4, PSAD 0.16, age 61, DRE Normal -> DEFER (uncertain). He wrote: "At what PSA level the prior biopsy was taken? If PIRADS 3 is new and PSA is significantly rising since last biopsy I would consider repeat biopsy an option"
  3. distance 2.01: PI-RADS 4, PSA 6.1, PSAD 0.08, age 63, DRE Normal -> BIOPSY (borderline). He wrote: "Rising PSA + PIRADS≥4 (limited size lesion) gives high probability of undetected prostate cancer. Therefore re-biopsy indicated. However, prev benign biopsy carries low…"

PRECEDENT: DEFER. The nearest precedent is this very patient, so the library returns what the reading urologist actually did with him. That is a record, not a judgement; out of sample this expert is worth only what the distance is worth.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. This patient is in the labelled series, so what follows is the reading urologist's own trace for him, not a prediction.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: comorbidity=noted, age=important, vol=important, bx=important, pirads=important, cspca=noted, fh=important, psa=important, dre=important, psad=important.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines address the use of MRI and biopsy in prostate cancer management. The guideline suggests that a PI-RADS score of $\ge 3$ is used to trigger a biopsy. It also notes that a PI-RADS threshold of $\ge 3$ would have avoided 30% of biopsy procedures while missing 11% of detected ISUP Grade Group 2 cancers in biopsy-naïve patients.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of no biopsy is not decisively supported by the guideline, as the guideline focuses on thresholds rather than the specific clinical context of a PI-RADS 3 finding in a patient with a prior negative biopsy. Expert 4's reliance on the panel variables alone is insufficient because the guideline suggests that the decision depends on risk factors like PSA density and PI-RADS score, which are present but not explicitly weighted by the guideline in this specific context.

WHAT WE STILL NEED
The guideline requires establishing the PSA density value to determine risk stratification. The panel shows the PSA density is $0.05 \text{ ng/mL}^2$. This value is needed to apply the risk-adapted matrix mentioned in the guideline. The prior biopsy status is documented as Negative, which is a known fact. The PI-RADS score is documented as 3, which is a known fact. The PSA velocity is documented as $-0.28 \text{ ng/mL/yr}$, which is a known fact. The prostate volume is documented as $58.0 \text{ mL}$, which is a known fact.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on establishing the clinical significance of the PI-RADS 3 finding in the context of a prior negative biopsy, as the EAU guideline requires establishing PSA density for risk stratification.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone of the MRI finding?
  psa_trend (get_psa_trend) -> What is the trend of the serial PSA values?
  previous_notes (get_previous_notes) -> What was the GRADE (Gleason or ISUP) of the prior negative biopsy, and is there an active surveillance protocol?
  laboratory_results (get_lab_results) -> What is the full panel including free-PSA fraction, renal function, and haemoglobin?

On the plan itself: Dropped 2 question(s) that asked for a value already printed on the panel: "What is the clinical significance of the PI-RADS 3 finding in this patient with a prior negative biopsy?".

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Subject: Prostate Multiparametric MRI | Facility: Antoni van Leeuwenhoek Hospital | Date: 15 January 2025
What is the lesion size and zone of the MRI finding? A roughly 12 mm focus of intermediate signal intensity located mid-gland within the right peripheral zone.

psa_trend
What is the trend of the serial PSA values? The trend shows values of 2.3 ng/mL on May 2022, 2.5 ng/mL on Apr 2023, 2.9 ng/mL on Mar 2024, and 3.4 ng/mL on Feb 2025.

previous_notes
What was the GRADE (Gleason or ISUP) of the prior negative biopsy, and is there an active surveillance protocol? The GRADE of the prior negative biopsy is not recorded, and there is no active surveillance protocol mentioned.

laboratory_results
What is the full panel including free-PSA fraction, renal function, and haemoglobin? PSA is 3.4 ng/mL, Free PSA is 0.71 ng/mL, %Free PSA is 21%, Haemoglobin is 14.8 g/dL, Creatinine is 102 umol/L, and eGFR is >60 mL/min/1.73m2.

WHAT I DID NOT OPEN
family-history anamnesis, because the information was not required to answer the specific questions posed by the moderator.

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
PI-RADS 3 lesion in the right peripheral zone.
Rising PSA trend from 2.3 ng/mL to 3.4 ng/mL over the monitoring period.

Findings that argue AGAINST sampling this patient now:
Prior biopsy was negative.
PI-RADS score is 3, which is equivocal.

WHERE THIS LEANS
The findings suggest a need for further investigation given the PI-RADS 3 finding and the rising PSA trend, which aligns with the EAU guideline's focus on risk stratification via PSA density.
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: INDETERMINATE (uncertain). Last value 3.40 ng/mL over 4 points spanning 33 months; velocity +0.40 ng/mL per year; doubling time about 58 months.
PROJECTION at 6 months: 4.0 ng/mL, conformal 95% band 1.2-14.0.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.29
  uncertainty  +/- 0.17 epistemic (95% band 0.00-0.62), of which 0.00 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.33  ('supports' tier)
  EXPERT-FUSION      DEFER, p(biopsy)=0.29  ('supports' tier, fusion_full)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.02  (identical panel in the series)
  EXPERT-COHORT      DEFER  (rule pirads_le_3)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: identical precedent in the labelled series — carried by EXPERT-LIBRARY.
PANEL ANSWER: NO BIOPSY. The labelled series contains this exact panel; the library returns the reading urologist's own decision for it. Out of sample this rung never fires.

Confidence the trace model expects here: clear. Weights it expects: comorbidity=noted, age=important, vol=important, bx=important, pirads=important, cspca=noted, fh=important, psa=important, dre=important, psad=important.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar appear to address the core variables needed for the decision, specifically providing the PI-RADS 3 finding from the MRI, the PSA trend, the prior biopsy status context from previous notes, and the full lab panel.

ALIGNMENT WITH THE PANEL
The retrieved evidence, particularly the PI-RADS 3 score and the rising PSA trend, leans towards a need for further investigation, which contradicts the PANEL-PROTOCOL's final answer of NO BIOPSY, which was driven by the EXPERT-LIBRARY precedent.

THE OPEN QUESTIONS, ONE BY ONE
Since no moderator questions were recorded, this step is moot; however, the key unresolved tension is whether the PI-RADS 3 finding combined with the rising PSA trend overrides the precedent-based decision.

WHAT CARRIES WEIGHT, AND WHY
The PI-RADS score (3) is critical as it is the primary driver for the EXPERT-COHORT rule that supports deferral. The rising PSA trend is also important as it suggests biological activity. The prior negative biopsy status is the most significant factor supporting the deferral decision.

MY SUGGESTION TO THE CHAIR
I suggest leaning towards a biopsy, as the combination of a PI-RADS 3 lesion and a rising PSA trend suggests a clinical scenario where the established precedent might be less applicable than the current imaging and trend data.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

The panel protocol suggested no biopsy based on an identical precedent in the labelled series, which is a strong factor. However, the Verifier suggested biopsy due to the PI-RADS 3 finding and the rising PSA trend. Since no retrieved finding explicitly overturns the precedent, I submit no biopsy, as the evidence converged on deferral despite the conflicting trend data.

What carried weight: comorbidity=noted, age=important, vol=important, bx=important, pirads=important, cspca=noted, psa=important, dre=important, psad=important
Documents this conference opened: radiology_report, psa_trend, previous_notes, laboratory_results
